cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Harpoon Therapeutics Inc
20 own
24 watching
Current Price
$4.1
$0.1
(2.5%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
28.95M
52-Week High
52-Week High
33.55000
52-Week Low
52-Week Low
3.86010
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization28.95M
icon52-Week High33.55000
icon52-Week Low3.86010
iconAverage Volume0.05M
iconDividend Yield--
iconP/E Ratio--
What does the Harpoon Therapeutics Inc do?
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More
How much money does Harpoon Therapeutics Inc make?
News & Events about Harpoon Therapeutics Inc.
Globe Newswire
5 months ago
Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor activity-secretase inhibitors increased the potency of HPN217 in vitro in multiple cell lines, supporting ...
Globe Newswire
5 months ago
Results support further investigation of two new ProTriTAC protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and integrin-beta6 (ITGB6)-expressing solid tumorsSOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- ...
Benzinga
9 months ago
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. read more...
PR Newswire
9 months ago
Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals? Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals? PR...
Globe Newswire
9 months ago
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses were durable, with many patients on treatment longer ...
Frequently Asked Questions
Frequently Asked Questions
What is Harpoon Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Harpoon Therapeutics Inc shares?
plus_minus_icon
How can I buy Harpoon Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Harpoon Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Harpoon Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Harpoon Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Harpoon Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Harpoon Therapeutics Inc?
plus_minus_icon
What percentage is Harpoon Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Harpoon Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.1
$0.1
(2.5%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00